Bio-Techne Announces Cell and Gene Therapy Initiative

MINNEAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Bio-Techne, a global leader of research and manufacturing-grade reagents, has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing. Through strategic acquisitions and internal scientific innovation, Bio-Techne has become uniquely positioned to provide a comprehensive, innovative, and flexible set of reagents and instrumentation across the cell and gene therapy workflow. In 2019, Bio-Techne will bring its multi-brand solutions together with the mission of providing "Pioneering Cell and Gene Therapy Solutions from Discovery to the Clinic."


Bio-Techne's solutions for the cell therapy workflow span its portfolio, including GMP-grade cytokines and growth factors, high-quality antibodies for flow cytometry and immunocytochemical characterization, gold-standard immunoassays and next-generation automated immunoassay platforms, DNA and RNA in situ hybridization (ISH) assays, GMP-grade small molecules, and more. The cell therapy initiative will unite these reagents to provide the cell therapy community with a rich and user-friendly resource for reagents, instrumentation, and scientific expertise across the cell therapy workflow.

"We recognize that improving the efficiency, quality, and safety of ex vivo manufacturing is extremely important as more and more researchers bring their cell therapy discoveries from the bench to the clinic," commented Sean Kevlahan, Senior Director of Cell and Gene Therapy at Bio-Techne. "The goals of our cell and gene therapy initiative are two-fold. First, we will provide and develop innovative solutions designed to simplify the workflow for both immune cell- and stem cell-based therapies, such as Cloudz™ Cell Activation Kits and SimplePlex™ assays. Second, we aim to make the transition from the bench to the bedside easier by providing progressive solutions that can be stepped through the journey from discovery to cell therapy manufacturing."

Dave Eansor, President of Bio-Techne's Protein Sciences Segment, commented, "We are excited to bring our brands together to advance cell and gene therapy discovery and manufacturing across the globe. This initiative will not only provide immediate workflow solutions; it will also facilitate development of new and innovative technologies to address the current and future manufacturing needs of the cell therapy community."

Forward-Looking Statements

Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations.  Forward-looking statements in this press release include statements regarding our belief about the market applications of various existing product lines and our ability to derive advantages from marketing such products for cell and gene therapy applications.  The following important factors, among others, have affected and, in the future could affect, our actual results: our management of the integration of new businesses into Bio-Techne, the effect of new branding and marketing initiatives, the integration of new leadership, the introduction and acceptance of new products, the levels and particular directions of research and product development by our customers, the impact of the growing number of producers of biotechnology research and diagnostics products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of our research and product development efforts and those of companies in which we have invested or with which we have formed strategic relationships. 

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

About Bio-Techne Corporation (NASDAQ: TECH)

CONTACT: Dave Eansor, President, Protein Sciences Segment, 612-379-2956


Cision View original content to download multimedia:

SOURCE Bio-Techne Corporation